These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34990728)

  • 1. Roflupram attenuates α-synuclein-induced cytotoxicity and promotes the mitochondrial translocation of Parkin in SH-SY5Y cells overexpressing A53T mutant α-synuclein.
    Zhong J; Li M; Xu J; Dong W; Qin Y; Qiu S; Li X; Wang H
    Toxicol Appl Pharmacol; 2022 Feb; 436():115859. PubMed ID: 34990728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson's disease models.
    Dong WL; Zhong JH; Chen YQ; Xie JF; Qin YY; Xu JP; Cai NB; Li MF; Liu L; Wang HT
    Acta Pharmacol Sin; 2021 Dec; 42(12):1991-2003. PubMed ID: 34531546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylation of Parkin at serine 131 by p38 MAPK promotes mitochondrial dysfunction and neuronal death in mutant A53T α-synuclein model of Parkinson's disease.
    Chen J; Ren Y; Gui C; Zhao M; Wu X; Mao K; Li W; Zou F
    Cell Death Dis; 2018 Jun; 9(6):700. PubMed ID: 29899409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p38 MAPK-DRP1 signaling is involved in mitochondrial dysfunction and cell death in mutant A53T α-synuclein model of Parkinson's disease.
    Gui C; Ren Y; Chen J; Wu X; Mao K; Li H; Yu H; Zou F; Li W
    Toxicol Appl Pharmacol; 2020 Feb; 388():114874. PubMed ID: 31881179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
    Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
    Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of mortalin/GRP75/mthsp70 in the mitochondrial impairments induced by A53T mutant α-synuclein.
    Liu FT; Chen Y; Yang YJ; Yang L; Yu M; Zhao J; Wu JJ; Huang F; Liu W; Ding ZT; Wang J
    Brain Res; 2015 Apr; 1604():52-61. PubMed ID: 25665531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant α-synuclein.
    Li XZ; Zhang SN; Wang KX; Liu HY; Yang ZM; Liu SM; Lu F
    Phytomedicine; 2014 Apr; 21(5):704-11. PubMed ID: 24252343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein Regulates Iron Homeostasis via Preventing Parkin-Mediated DMT1 Ubiquitylation in Parkinson's Disease Models.
    Bi M; Du X; Jiao Q; Liu Z; Jiang H
    ACS Chem Neurosci; 2020 Jun; 11(11):1682-1691. PubMed ID: 32379419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manganese-induced alpha-synuclein overexpression aggravates mitochondrial damage by repressing PINK1/Parkin-mediated mitophagy.
    Liu ZQ; Liu K; Liu ZF; Cong L; Lei MY; Ma Z; Li J; Deng Y; Liu W; Xu B
    Food Chem Toxicol; 2021 Jun; 152():112213. PubMed ID: 33862121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflupram, a Phosphodiesterase 4 Inhibitior, Suppresses Inflammasome Activation through Autophagy in Microglial Cells.
    You T; Cheng Y; Zhong J; Bi B; Zeng B; Zheng W; Wang H; Xu J
    ACS Chem Neurosci; 2017 Nov; 8(11):2381-2392. PubMed ID: 28605578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflupram, a novel phosphodiesterase 4 inhibitor, inhibits lipopolysaccharide-induced neuroinflammatory responses through activation of the AMPK/Sirt1 pathway.
    Li D; Xu J; Qin Y; Cai N; Cheng Y; Wang H
    Int Immunopharmacol; 2021 Jan; 90():107176. PubMed ID: 33243606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP
    Zhong J; Yu H; Huang C; Zhong Q; Chen Y; Xie J; Zhou Z; Xu J; Wang H
    Redox Biol; 2018 Jun; 16():47-58. PubMed ID: 29475134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson's disease.
    Jęśko H; Lenkiewicz AM; Wilkaniec A; Adamczyk A
    Acta Neurobiol Exp (Wars); 2019; 79(3):276-289. PubMed ID: 31587020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.
    Choong CJ; Say YH
    Neurotoxicology; 2011 Dec; 32(6):857-63. PubMed ID: 21658409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of α-synuclein and Parkin in iron toxicity on SH-SY5Y cells: implications in the pathogenesis of Parkinson's disease.
    Ganguly U; Banerjee A; Chakrabarti SS; Kaur U; Sen O; Cappai R; Chakrabarti S
    Biochem J; 2020 Mar; 477(6):1109-1122. PubMed ID: 32108853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of wild-type and A53T mutant isoform of alpha-synuclein on the mitochondrial proteome of differentiated SH-SY5Y cells.
    Pennington K; Peng J; Hung CC; Banks RE; Robinson PA
    J Proteome Res; 2010 May; 9(5):2390-401. PubMed ID: 20334438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roflupram exerts neuroprotection via activation of CREB/PGC-1α signalling in experimental models of Parkinson's disease.
    Zhong J; Dong W; Qin Y; Xie J; Xiao J; Xu J; Wang H
    Br J Pharmacol; 2020 May; 177(10):2333-2350. PubMed ID: 31972868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells.
    Perfeito R; Lázaro DF; Outeiro TF; Rego AC
    Mol Cell Neurosci; 2014 Sep; 62():51-9. PubMed ID: 25109238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of MAPK attenuates neuronal cell death induced by activated glia-conditioned medium in alpha-synuclein overexpressing SH-SY5Y cells.
    Yshii LM; Denadai-Souza A; Vasconcelos AR; Avellar MC; Scavone C
    J Neuroinflammation; 2015 Oct; 12():193. PubMed ID: 26502720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
    Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
    Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.